New bone graft shows promise in helping spine surgery patients heal

NCT ID NCT05972616

Completed Disease control Sponsor: Induce Biologics USA Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well a bone graft material called Natural Matrix Protein (NMP™) works in 53 patients who had spinal fusion surgery for degenerative disc disease. The main goal was to see if the bones fused properly on CT scans and X-rays. Researchers also measured changes in disability using a patient questionnaire. The study is completed and provides early data on this product's performance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Natural Matrix Protein (NMP) - a human bone allograft used to promote spinal fusion
What this could lead to: If successful, this could confirm that NMP™ is a safe and effective option for helping bones fuse after spinal surgery, potentially improving surgical outcomes.
What could go wrong: This is a small, single-center review with no comparison group, so results may not apply to all patients. The study is completed but only evaluates short-term fusion and disability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEGENERATIVE DISC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intervertebral disk degenerative disorder lumbar disk degenerative disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEGENERATIVE DISC DISEASE

Contacts and locations

Locations

Spine Institute of Louisiana

Shreveport, Louisiana, 71101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.